Publications: PubMed

Division of Microbiology
Tulane National Primate Research Center
18703 Three Rivers Road
Covington, Louisiana 70433

Phone: 985-871-6290

Fax: 985-871-6248


Other profile(s):

Tulane School of Medicine

Vicki L. Traina-Dorge, Ph.D.

Associate Professor, Division of Microbiology, TNPRC

Associate Professor, Microbiology & Immunology, SOM


B.S., Biology, Jacksonville State University, Jacksonville, AL

M.T. (ASCP), Medical Technology, Caraway Methodist Medical Center, Birmingham, AL

Ph.D., Microbiology and Immunology, Tulane University Medical Center, New Orleans, LA

Research Programs

  • Varicella Virus Infection, Latency, and Reactivation
  • Varicella based AIDS Vaccine
  • Papillomavirus Infection and Progression to Cervical Cancer
  • Respiratory Syncytial Virus Infection and Pathogenesis

Research Interests:

Dr. Traina-Dorge is an Associate Professor of Microbiology and Immunology at the Tulane University School of Medicine and a Molecular Virologist within the Division of Microbiology at the Tulane National Primate Research Center (TNPRC), Covington, Louisiana. She has a broad background in virology, immunology, and pathogenesis of nonhuman primates (NHP). This includes over twenty years’ experience developing NHP models of pathogenic viral infections that include agents: simian immunodeficiency virus (SIV), simian T cell lymphotropic virus (STLV), simian varicella virus (SVV), respiratory syncytial virus (RSV), rhesus papillomavirus (RhPV), mouse mammary tumor virus (MMTV), and alphaviruses: Eastern and Western equine encephalitis viruses (EEE and WEE) to study of molecular mechanisms of viral pathogenesis, carcinogenesis, molecular epidemiology, and vaccine development. Following development of a NHP model of shingles/zoster, her lab is currently working to identify cell types and cell signaling molecules for SVV trafficking in virus reactivation and onset of shingles. They are developing and testing a live attenuated recombinant SVV-SIV vaccine for both protective and therapeutic treatments against SIV challenge in the NHP, with ultimate development towards a vaccine against HIV. They are also developing a NHP cervical cancer model with RhPV, having demonstrated genital infection with RhPV that produces precancerous lesions, with increased frequency upon immunosuppression and co-infection with SIV, similar to that seen in AIDS patients. Finally, her laboratory is studying the protective efficacy of a virus-like-particle (VLP) vaccines against pathogenic alphaviruses (EEE and WEE).

The TNPRC is a division of Tulane University (985) 871-6201